Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFIC	CIAL OWNERSHI)

ON	OMB APPROVAL									
OMB Nu	OMB Number: 3235-0287									
Estimate	Estimated average burden									
hours pe	hours per response:									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SIMARD JOHN					2. Issuer Name and Ticker or Trading Symbol XBiotech Inc. [XBIT]								k all app	ionship of Reportii all applicable) Director		rson(s) to Is	Owner		
(Last) (First) (Middle) 5217 WINNEBAGO LANE						3. Date of Earliest Transaction (Month/Day/Year) 09/23/2021						X	belov	er (give title v) Chief Exect	utive	Other (s below)	specify		
(Street) AUSTIN TX 78744					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc Line)					``	
(City)						Form filed by More than One Reporting Person													
		Table	1 - 1	Non-Deriva	tive	Secu	rities	Ac	quir	ed, D	isposed	of, or	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Ye	Execu Year) if any		2A. Deemed Execution Date, f any Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar				Secur Benef Owne	rities Fe ficially (E ed Following In		m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D)	Price	•		erted (In saction(s) : 3 and 4)		tr. 4)	(Instr. 4)	
Common Stock				09/23/202	21				S		9,892	D	\$14	.6805(1	4,1	4,113,274		D	
Common Stock 09				09/24/202	1				S		11,418	D	\$14	.4867(1	4,1	4,101,856		D	
Common Stock				09/27/202	21						29,890	D	\$14.814(1)		4,071,966		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)					rative rities ired r osed) . 3, 4	Ex (Me	Date Ex piration onth/Da		Am Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	/ E	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Da Ex	te ercisab	Expiration	on Title	or Nun of						

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

John Simard, CEO Chairman of XBiotech, Inc., adopted a stock trading plan. He sold total of 512,000 common stock on the open market as part of this 10B5-1 trading plan.

/s/ Queena Han under Power of Attorney for John Simard

09/28/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.